Decreased interleukin-10 and increased interleukin- 12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

Annals of Neurology

Volumn 45, Issue 6, 1999, Pages 695-703

  Van Boxel Dezaire, A H H ^a,b   Hoff, S C J ^a   Van Oosten, B W ^b   Verweij, C L ^a   Drager A M ^b   Ader H J ^b   Van Houwelingen, J C ^a   Barkhof, F ^b   Polman, C H ^b   Nagelkerken, L ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; BRAIN; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; RECURRENCE; RNA, MESSENGER;

EID: 0032975730     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R     Document Type: Article

References (36)

1. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409-421
2. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435
3. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-1996
4. Selmaj K, Raine CS, Cannella B, et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954
5. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323
6. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472
7. Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Arch Neurol 1992;49:265-270
8. Drulovic J, Mostarica-Stojkovic M, Levic Z, et al. Interleukin-12 and tumor necrosis factor-α levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997;147: 145-150
9. Martino G, Consiglio A, Franciotta DM, et al. Tumor necrosis factor-α and its receptors in relapsing-remitting multiple sclerosis. J Neurol Sci 1997;152:51-61
10. Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-1526
11. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88
12. Spuler S, Yousry T, Scheller A, et al. Multiple sclerosis: prospective analysis of TNF-α and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 1996;66:57-64
13. Sarchielli P, Orlacchio A, Vicinanza F, et al. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J Neuroimmunol 1997;80:76-86
14. Rovaris M, Barnes D, Woodrofe N, et al. Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol 1996;243:536-542
15. Van Oosten BW, Barkhof F, Scholten PE, et al. Increased production of tumor necrosis factor α, and not of interferon γ, preceding disease activity in patients with multiple sclerosis. Arch Neurol 1998:55:793-798
16. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-4027
17. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995;181:381-386
18. Van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49: 351-357
19. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDDS). Neurology 1983; 33:1444-1452
21. Bouaboula M, Legoux P, Pességué B, et al. Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multi specific internal control. J Biol Chem 1992;267:21830-21838
22. Visser J, van Boxel-Dezaire A, Methorst D, et al. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998;91:4255-4264
23. Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996;70:87-90
24. Ferrante P, Fusi ML, Saresella M, et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 1998;160:1514-1521
25. + T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599-603
26. Gerritse K, Laman JD, Noelle RJ et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93:2499-2504
27. Issazadeh S, Ljungdahl A, Hojeberg B, et al. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta. J Neuroimmunol 1995;61:205-212
28. Smith T, Hewson AK, Kingsley CI, et al. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997;150:1909-1917
29. Segal BM, Dwyer BK, Shevach EM. An inrerleukin (IL)-10/ IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998;187:537-546
30. Navikas V, Link J, Palasik W, et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995;41:171-178
31. Salmaggi A, Dufour A, Eoli M, et al. Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression? J Neurol 1996;243:13-17
32. Musette P, Benveniste O, Lim A, et al. The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis. Res Immunol 1996;147:435-441
33. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102:671-678
34. Guéry JC, Ria F, Galbiati F, et al. Normal B cells fail to secrete interleukin-12. Eur J Immunol 1997;27:1632-1639
35. Munschauer FE, Hartrich LA, Stewart CC, et al. Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls. J Neuroimmunol 1995; 62:177-181
36. Oksaranta O, Tarvonen S, Ilonen J, et al. T-cell subpopulations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: a follow-up study. Neurology 1996;47:1542-1545